Ruxolitinib inhibits IFN γ licensing of human bone marrow derived Mesenchymal Stromal Cells

Ruxolitinib is a small molecule inhibitor of JAK2/JAK1 kinases1. Ruxolitinib was initially approved for the treatment of ABL-negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis that are caused by the aberrant activation of the JAK-STAT pathway in hematopoietic cells2, 3. Ruxolitinib is also being clinically investigated for treatment of non-myeloproliferative disorders including irritable bowel disease, rheumatoid arthritis, psoriatic skin lesions and Graft versus Host Disease (GVHD)4, 5.

Source: Biology of Blood and Marrow Transplantation - February 3, 2021 Category: Hematology Authors: Molly Mercedes Ryan, Mihir Patel, Keenan Hogan, Ariel Joy Lipat, Rafaela Scandolara, Rahul Das, Charles Bruker, Jacques Galipeau, Raghavan Chinnadurai Source Type: research